- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06798896
Renaissance 2: SPN-817 Fase 2, dubbelblinde, placebo-gecontroleerde studie bij volwassenen met focale aanval van het begin
Renaissance 2: een dubbelblinde, gerandomiseerde, placebo-gecontroleerde, multicenter-, parallelle-groepsstudie om de werkzaamheid, veiligheid en verdraagbaarheid van SPN-817 bij volwassenen te evalueren met focale aanval van het begin
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Navid Saeidi, MS
- Telefoonnummer: 240-403-5328
- E-mail: nsaeidi@supernus.com
Studie Contact Back-up
- Naam: Supernus Clinical Trials
- Telefoonnummer: 240-403-5838
- E-mail: clinicaltrials@supernus.com
Studie Locaties
-
-
Queensland
-
Herston, Queensland, Australië, 4029
- Werving
- Royal Brisbane and Women's Hospital
-
-
South Australia
-
Adelaide, South Australia, Australië, 5000
- Werving
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australië, 3168
- Werving
- Monash Medical Centre
-
Fitzroy, Victoria, Australië, 3065
- Werving
- St. Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australië, 3004
- Werving
- The Alfred Hospital
-
Parkville, Victoria, Australië, 3052
- Werving
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- The Perron Institute for Neurological and Translational Science
-
-
-
-
-
Blagoevgrad, Bulgarije, 2700
- Werving
- Multiprofile Hospital for Active Treatment PULS
-
Pleven, Bulgarije, 5809
- Werving
- Medical Center (MC) Academica
-
Rousse, Bulgarije, 7012
- Werving
- Medical Center - Teodora EOOD
-
Sofia, Bulgarije, 1113
- Werving
- Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgarije, 1431
- Werving
- University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
-
-
-
-
-
Budapest, Hongarije, 1125
- Werving
- Flash Clinic
-
Budapest, Hongarije, 1145
- Werving
- SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
-
-
-
-
-
Lublin, Polen, 20-064
- Werving
- NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Werving
- Pratia MCM Kraków
-
-
Maloplski
-
Krakow, Maloplski, Polen, 30-363
- Werving
- Centrum Medyczne Plejady
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 01-684
- Werving
- Centrum Medyczne NeuroProtect
-
Warsaw, Masovian Voivodeship, Polen, 02-172
- Werving
- TZ Clinical Research powered by Pratia
-
Warsaw, Masovian Voivodeship, Polen, 02-952
- Werving
- Neurosphera
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polen, 81-537
- Werving
- Synexus Polska Sp. z o. o. Oddział w Gdyni
-
Sopot, Pomeranian Voivodeship, Polen, 81-735
- Geschorst
- Terra Centrum Leczenia
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-123
- Werving
- NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
-
Katowice, Silesian Voivodeship, Polen, 40-650
- Werving
- Novo-Med Zieliński i Wsp. Sp.J.
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85004
- Werving
- Xenoscience
-
Phoenix, Arizona, Verenigde Staten, 85006
- Werving
- Banner University Medical Center-Phoenix
-
Tucson, Arizona, Verenigde Staten, 85724
- Werving
- University of Arizona College of Medicine - Tucson
-
Tucson, Arizona, Verenigde Staten, 85718
- Werving
- Center for Neurosciences
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Werving
- Clinical Trials, Inc
-
-
California
-
Los Angeles, California, Verenigde Staten, 90048
- Werving
- Clinical Research Institute
-
Mission Hills, California, Verenigde Staten, 91345
- Werving
- Access Community Clinical Trials
-
Orange, California, Verenigde Staten, 92868
- Werving
- University of California, Irvine
-
West Hills, California, Verenigde Staten, 91307
- Werving
- Focus Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Yale University
-
-
Florida
-
Gulf Breeze, Florida, Verenigde Staten, 32561
- Werving
- Northwest Florida Clinical Research Group, LLC
-
Kissimmee, Florida, Verenigde Staten, 34744
- Werving
- Ilumina Medical Research
-
Miami, Florida, Verenigde Staten, 33136
- Werving
- University of Miami
-
Miami, Florida, Verenigde Staten, 33133
- Werving
- Visionary Investigators Network
-
Orlando, Florida, Verenigde Staten, 32806
- Beëindigd
- Research Institute of Orlando, LLC
-
Port Charlotte, Florida, Verenigde Staten, 33952
- Werving
- Medsol Clinical Research Center
-
Contact:
- Maria Vasconcelos, RN
- Telefoonnummer: 941-623-9744
- E-mail: mvasconcelos@medsolcrc.com
-
Port Saint Lucie, Florida, Verenigde Staten, 34990
- Werving
- Cleveland Clinic Florida Martin Health
-
-
Illinois
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Southern Illinois University School of Medicine
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40223
- Werving
- University of Louisville Physicians
-
-
Louisiana
-
Covington, Louisiana, Verenigde Staten, 70433
- Werving
- Neurocare of Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70121
- Geschorst
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Werving
- Johns Hopkins University
-
Bethesda, Maryland, Verenigde Staten, 20817
- Werving
- Mid Atlantic Epilepsy and Sleep Center
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Werving
- Wayne State University - Detroit Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Werving
- Northeast Regional Epilepsy Group - Hackensack
-
Neptune City, New Jersey, Verenigde Staten, 07753
- Werving
- Hackensack Meridian Health Jersey Shore University Medical Center
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Werving
- Albany Medical Center
-
Amherst, New York, Verenigde Staten, 14226
- Werving
- Dent Neurologic Institute
-
New York, New York, Verenigde Staten, 10021
- Werving
- Northwell Health - Lenox Hill
-
Rochester, New York, Verenigde Staten, 14618
- Werving
- University of Rochester Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Verenigde Staten, 28806
- Werving
- Asheville Neurology Specialists
-
Charlotte, North Carolina, Verenigde Staten, 28211
- Werving
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Neurology Institute Epilepsy Center of Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Werving
- Thomas Jefferson University
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt University Medical Center
-
-
Texas
-
El Paso, Texas, Verenigde Staten, 79912
- Werving
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
Frisco, Texas, Verenigde Staten, 75034
- Werving
- Stryde Research
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- UT Health Houston
-
-
Virginia
-
McLean, Virginia, Verenigde Staten, 22101
- Werving
- Medstar Health Research Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
- Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
- Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
- Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
- Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
- At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;
Exclusion Criteria:
- Has taken huperzine A within the past 6 months;
- Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
- History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
- Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
- History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
- History of status epilepticus within 6 months prior to screening;
- Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
- Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
- Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
- History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
- Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: SPN-817
SPN-817, bid |
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid |
|
Placebo-vergelijker: Placebo
Placebo, bid |
Placebo, bid |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
Tijdsspanne: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Tijdsspanne: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline. |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
|
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
Tijdsspanne: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Tijdsspanne: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Longest seizure-free interval over the entire Treatment Period
Tijdsspanne: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
The longest intervals in days between two seizures during the entire Treatment Period. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Incidence of treatment-emergent adverse events (TEAEs)
Tijdsspanne: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment. |
Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 817P203
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .